articleTop 1% cited

Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 *

JNCI Journal of the National Cancer Institute · 1994 · Vol. 86(7) · pp. 527–537

B. Fisher✉(University of Pittsburgh)Joseph P. CostantinoCarol RedmondE R FisherD. Lawrence WickerhamWalter M. CroninOther NSABP Contributors

View via DOI Publisher page

Abstract

Tamoxifen treatment for breast cancer should continue. In addition, the relative risk of endometrial cancer observed in B-14 tamoxifen-treated patients is consistent with the twofold relative risk used in the initial risk-benefit computation for the NSABP breast cancer prevention trial.

Estrogen and related hormone effects Endometrial and Cervical Cancer Treatments Inflammatory mediators and NSAID effectsTamoxifenMedicineEndometrial cancerBreast cancerCancerHazard ratioOncologyInternal medicineGynecologyAntiestrogen

MeSH terms

AdultAgedBreast NeoplasmsFemaleFollow-Up StudiesHumansMiddle AgedTamoxifenScientific MisconductIncidenceOdds RatioSurvival AnalysisNeoplasms, Second PrimaryEndometrial Neoplasms

Citations

1,275

FWCI

34.82

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Coactivator and Corepressor Regulation of the Agonist/Antagonist Activity of the Mixed Antiestrogen, 4-Hydroxytamoxifen